Traffic Lights - Latest Updates

Last updated: 05/09/2022

Other updates on this site
Drug Name Classification Clinical Indication Comments
BUSERELIN (Suprecur®) (UPDATED) Red IVF

Regulation restricts the prescribing and supply of puberty-suppressing hormones to children and young people under 18

The Medicines (Gonadotrophin-Releasing Hormone Analogues) (Emergency Prohibition) (England, Wales and Scotland) Order 2024 (legislation.gov.uk) 

DARIDOREXANT (Quviviq®) (UPDATED) Green Treating long-term insomnia

Management of long term insomnia in primary care Chronic Insomnia Pathway

In line with NICE TA922

DENOSUMAB (Xgeva®) (UPDATED) Red Prevention of skeletal related events for myeloma patients with CKD (GFR <10ml/min)

Denosumab Evaluation 

ENOXAPARIN Red Acute coronary syndrome
ENOXAPARIN (UPDATED) Green Thromboprophylaxis and treatment of DVT

Prescribe by brand name INHIXA® as different brands have different injection techniques.

Courses started during the dalteparin shortage can be continued to be supplied in primary care

ENOXAPARIN (Inhixa®) Yellow Antenatal Indications
GONADORELIN ANALOGUES (UPDATED) Yellow Gender reassignment

Must be prescribed in line with recommendations from specialist. The nearest specialist is Nottingham.

Regulation restricts the prescribing and supply of puberty-suppressing hormones to children and young people under 18

GOSERELIN Green Prostatic carcinoma

GP can give first injection to patients in whom anti-androgen treatment has been started by secondary care clinician.

Local guidance

Regulation restricts the prescribing and supply of puberty-suppressing hormones to children and young people under 18

GOSERELIN 3.6mg (Zoladex®) (UPDATED) Yellow Breast cancer

Zoladex 3.6mg implant is the only licensed product for breast cancer

 

 

ICOSAPENT ETHYL (Vazkepa ®) (UPDATED) Green Raised triglycerides in patients with CVD

LLR Lipid pathway

LEUPRORELIN (UPDATED) Green Prostate cancer (subcutaneous injection for patients at risk of haematoma)

GP can give first injection to patients in whom anti-androgen treatment has been started by secondary care clinician.

Local guidance

Regulation restricts the prescribing and supply of puberty-suppressing hormones to children and young people under 18

METHOTREXATE Oral (UPDATED) Orange Rheumatological disease

Full SCA     Request form

Always prescribe oral Methotrexate in multiples of 2.5mg tablet strength. The 10mg tablets must NOT be prescribed or supplied.

METHOTREXATE Oral (UPDATED) Orange Dermatological disease

Full SCA

Always prescribe oral Methotrexate in multiples of 2.5mg tablet strength. The 10mg tablets must NOT be prescribed or supplied

METHOTREXATE Oral (UPDATED) Red Severe refractory asthma

Always prescribe oral Methotrexate in multiples of 2.5mg tablet strength. The 10mg tablets must NOT be prescribed or supplied

METHOTREXATE Oral (UPDATED) Orange Crohn's Disease

Full SCA

Always prescribe oral Methotrexate in multiples of 2.5mg tablet strength. The 10mg tablets must NOT be prescribed or supplied

TRIPTORELIN (UPDATED) Yellow Precocious puberty

GP Guidance

Regulation restricts the prescribing and supply of puberty-suppressing hormones to children and young people under 18

 

Other Updates on this Website

Recent documents from LLR APC and TAS


About the Leicester, Leicestershire and Rutland Area Prescribing Committee

In common with other local health communities, the Leicester, Leicestershire and Rutland Area Prescribing Committee (LLR APC) acknowledges the benefits of having a Leicestershire Health Community-wide strategy for the prescribing of specialist medicines and the managed entry of new drugs and related technologies.

Leicestershire Health Community comprises the Leicester, Leicestershire and Rutland Integrated Care Board, University Hospitals of Leicester (UHL) NHS Trust and Leicestershire Partnership NHS Trust (LPT), amongst which there is a total consensus on the need for this strategy, and the LLR APC has been in place since 2005. Learn more